Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B, Shim JS. · 2016
Read Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer. by Du B, Shim JS. (2016) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6273543.txt.
Introduction
Du and Shim review a cell change that helps cancers resist drugs. Their review appeared in Molecules. The change is called epithelial-mesenchymal transition, or EMT. Cells that switch gain traits like cancer stem cells. They pump drugs out faster and resist death signals. That shift has become a key cause of treatment failure.
Many signalling pathways feed the switch. The review maps how each pathway supports drug resistance. It also gathers new work on blocking the switch. Targeting EMT could restore drug sensitivity in resistant tumours. The authors note debate over EMT's role in spread itself. Its role in resistance is now much firmer. The review gives researchers a map of pathways to target. It also warns that blocking one path may not be enough.
Catalog record
| CREATOR | Du B, Shim JS. |
|---|---|
| YEAR | 2016 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Targeting Epithelial–Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer By Bowen Du, Joong Sup Shim, Helena Vasconcelos Published in: Molecules DOI: 10.3390/molecules21070965 ABSTRACT Abstract Epithelial–mesenchymal transition (EMT) is known to play an important role in cancer progression, metastasis and drug resistance. Although there are controversies surrounding the causal relationship between EMT and cancer metastasis, the role of EMT in cancer drug resistance has been increasingly recognized. Numerous EMT-related signaling pathways are involved in drug resistance in cancer cells. Cells undergoing EMT show a feature similar to cancer stem cells (CSCs), such as an increase in drug efflux pumps and anti-apoptotic effects. Therefore, targeting EMT has been considered a novel opportunity to overcome cancer drug resistance. This review describes the mechanism by which EMT contributes to drug resistance in cancer cells and summarizes new advances in research in EMT-associated drug resistance. Keywords: epithelial–mesenchymal transition, drug resistance, chemotherapy, cancer stem cells 1. INTRODUCTION Cancer is one of the leading causes of human death. Despite significant advances in cancer research throughout the decades, treatment of cancer is still facing serious challenges. Chemotherapy is one of the well-established types of cancer treatment and has long been used as monotherapy or in combination with surgery or radiotherapy to treat cancer patients. However, chemotherapy drugs, both classical cytotoxic drugs and molecular targeted drugs, have been challenged by drug resistance, a major cause of cancer treatment failure and cancer-related mortality. In the last decade, tremendous effort has been paid to develop targeted cancer therapies. A number of monoclonal antibody drugs and small molecules, especially kinase inhibitors, have been developed and entered clinic in the hope of improving anticancer efficacy. While many of the targeted therapy drugs showed promising early clinical outcomes with improved overall survival, a large number of the patients receiving targeted therapy developed drug resistance after long-term drug administration [1]. Currently, more than 100 targeted cancer therapy drugs have been approved for cancer patients and much more are in clinical investigations. Therefore, cancer drug resistance will be a key factor to determine the success of the upcoming targeted therapy drugs. Drug resistance (or chemoresistance) can be divided into two groups: intrinsic (or de novo) drug resistance and acquired drug resistance [2,3]. Intrinsic drug resistance refers that the resistance factors have existed in the bulk of tumor cells before the drug treatment, whereas acquired drug resistance comes from that the resistance factors are developed during the drug treatment. Drug resistance arises from a broad range of mechanisms, such as drug efflux, drug metabolism, drug target mutations, etc. Recently, epithelial–mesenchymal transition (EMT) has received increasing attention for its role in cancer drug resistance. This review will focus on the link between EMT and drug resistance. 2. EMT-RELATED SIGNALING PATHWAYS EMT is the process that epithelial cells lose the apical-basal polarity and cell–cell adhesion, and transit to invasive mesenchymal cells. Mesenchymal–epithelial transition (MET), on the other hand, is the reverse process of EMT that involves the transition of cells from motile, multipolar mesenchymal types to polarized epithelial types. EMT are involved in numerous biological and pathological processes, including embryonic development, wound healing, cancer cell metastasis and drug resistance [4,5,6]. EMT refers to diverse changes in cells at a molecular level. Cells undergoing EMT display decreased expression level of epithelial genes (such as E-cadherin, ZO-1 and occludin) and increased expression level of mesenchymal genes (such as N-cadherin, vimentin and fibronectin) [7]. In most cases, loss of E-cadherin is a hallmark of EMT. The changes in gene expression during EMT lead to numerous phenotypic changes, such as cell morphological changes, loss of adhesion and gain of stem cell-like features [7]. Several key signaling pathways, including transforming growth factor beta (TGFβ), Wnt, Notch and Hedgehog, are known to be involved in EMT [8]. Signaling pathways that are related to EMT and their transcription targets that play a critical role in EMT are summarized in Figure 1. TGFβ pathway can be activated by binding TGFβ superfamily of ligands, including TGFβs, bone morphogenetic proteins (BMPs) and Nodal, to their cognate TGFβ receptors. Upon stimulation of TGFβ receptors, TGFβ signaling is divided into SMAD-dependent and SMAD-independent pathways. In the SMAD-dependent pathway, expression of the mesenchymal genes, such as vimentin, can be induced by SMAD complex upon activation of TGFβ receptor [9]. [Figure: Diverse signaling pathways associated with epithelial–mesenchymal transition (EMT). Transforming growth factor beta (TGFβ) signals activate SMAD2 and SMAD3 that complex with SMAD4. The trimeric SMAD complex enters the nucleus and leads to the transcription of EMT transcription factors (EMT-TFs) [9]. Activation of Wnt signaling inhibits the destruction complex containing glycogen synthase kinase 3 beta (GSK-3β) through Disheveled (DSH), facilitating β-catenin to enter the nucleus and activate the Snail transcription [10]. Notch receptors can be activated by binding to Delta and Jagged ligands. After activation, Notch intracellular domain (Notch-IC) is released through a cascade of proteolytic cleavages and activates CSL transcription factor to express EMT-TFs [11]. In Sonic Hedgehog (SHH) signaling, ligand binding to Patched 1 (PTCH1) receptors activates Smoothened (SMO) and Glioma (GLI) family transcription factors that induce Snail expression [12]. Interleukin-6 (IL-6) can induce Snail expression by activating STAT3 [13].] In the SMAD-independent pathway, TGFβ signal can induce EMT through GTPases, PI3K and MAPK pathways [14]. Other signaling pathways, including Notch [11], Wnt [10], Hedgehog [12], AKT-mTOR [15], MAPK/ERK [16], NF-κB [17] pathways, are also involved in EMT. These signaling pathways ultimately lead to an activation of EMT transcription factors (EMT-TFs). Several transcription factors have been identified as master regulators of EMT, including SNAIL factors (SNAI1, also known as Snail and SNAI2, also known as Slug), bHLH factors (E12 and E47, TWIST1 and TWIST2) and ZEB factors (ZEB1 and ZEB2) [7]. There are also some newly discovered EMT-TFs, such as SOX and FOX transcription factors. These EMT-TFs bind to specific DNA sequences, such as E-box to regulate EMT-target genes [7]. E-cadherin is a well-known transcription target for repression by Snail and many other EMT-TFs [18,19,20]. In addition to E-cadherin, a number of key proteins that are involved in epithelial cell–cell junction formation and cytoskeletal and polarity complex proteins are major transcription targets of EMT-TFs [7]. Epithelial cell–cell junction proteins, including occludin, claudins and desmoplakin as well as E-cadherin are targets for transcription repression, and cytoskeletal and polarity complex proteins, such as fibronectin, vitronectin, vimentin, N-cadherin and matrix metalloproteinases (MMPs) are targets for transcription activation [21,22,23]. 3. EMT AND CANCER DRUG RESISTANCE The link between EMT and cancer cell drug resistance has been suggested in the early 1990s. Sommers et al. found that two adriamycin-resistant MCF-7 cell lines and a vinblastine-resistant ZR-75-B cell line underwent EMT [24]. Adriamycin-resistant MCF-7 cells showed a significant increase in vimentin expression and have reduced formation of desmosomes and tight junctions, a typical phenotype in EMT. Not all of the drug-resistant MCF-7 cells exhibited EMT phenotypes, suggesting that among the heterogenic cancer cell population, EMT cells have selective growth advantage in the presence of drugs. It has been increasingly recognized that cancer drug resistance is frequently accompanied with EMT in diverse cancer, including pancreatic cancer [25], bladder cancer [26] and breast cancer [27]. Very recently, two research groups demonstrated a causal relationship between EMT and cancer drug resistance using genetically-engineered mice models [28,29]. Fischer et al.